Results 111 to 120 of about 2,490,885 (297)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Antibodies to biotin enable large-scale detection of biotinylation sites on proteins

, 2017
Namrata D. Udeshi, Kayvon Pedram, Tanya Svinkina, Shaunt Fereshetian, Samuel A. Myers, Ozan Aygün, Karsten Krug, Karl R. Clauser, Dominic M. Ryan, Tslil Ast, Vamsi K. Mootha, Alice Y. Ting, Steven A. Carr   +12 more
openalex   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody

Pharmaceuticals
Background/Objectives: Finotonlimab (SCTI10A) is a humanized anti-PD-1 antibody tested in Phase III trials for several solid tumor types. Methods: This study characterized the in vitro and in vivo efficacy, Fc-mediated effector function, and non-clinical
Yunqi Yao, Xiaoning Yang, Jing Li, Erhong Guo, Huiyu Wang, Chunyun Sun, Zhangyong Hong, Xiao Zhang, Jilei Jia, Rui Wang, Juan Ma, Yaqi Dai, Mingjing Deng, Chulin Yu, Lingling Sun, Liangzhi Xie   +15 more
doaj   +1 more source

Neutralization antibody titers against SARS-CoV-2 in an infant born to a mother with COVID-19 [PDF]

, 2021
Yi-Ching Chen, Yu-An Kung, Rajendra Prasad Janapatla, Mei‐Hua Hsu, Reyin Lien, Jeng‐Chang Chen, Shin‐Ru Shih, Cheng‐Hsun Chiu   +7 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining

Nature Communications
We describe a process for rapid antibody affinity optimization by repertoire mining to identify clones across B cell clonal lineages based on convergent immune responses where antigen-specific clones with the same heavy (VH) and light chain germline ...
Yi-Chun Hsiao, Heidi Ackerly Wallweber, Robert G. Alberstein, Zhonghua Lin, Changchun Du, Ainhoa Etxeberria, Theint Aung, Yonglei Shang, Dhaya Seshasayee, Franziska Seeger, Andrew M. Watkins, David V. Hansen, Christopher J. Bohlen, Peter L. Hsu, Isidro Hötzel   +14 more
doaj   +1 more source

Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery

, 2017
Daniela Alejandra Quinteros, José Marı́a Ancochea Bermúdez, Soledad Ravetti, Alicia Graciela Cid, Daniel A. Allemandi, Santiago Daniel Palma   +5 more
openalex   +2 more sources

Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides [PDF]

, 2013
Matteo Castelli, Francesca Cappelletti, Roberta A. Diotti, Giuseppe A. Sautto, Elena Criscuolo, Matteo Dal Peraro, Nicola Clementi   +6 more
openalex   +1 more source